$GH

Talasaz AmirAli sold $39.3M of GH (indirect holdings)

Talasaz AmirAli (Co-Chief Executive Officer) sold 260,000 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $151.20 ($150.49–$153.00, $39.31M total) across 6 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Talasaz AmirAli
Published Jun 30, 2026, 9:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosure provides a concrete, time-stamped insider selling datapoint (size, price range, and post-transaction holdings). However, absent any new operational or regulatory development, it is more likely to influence short-term sentiment than valuation.

02

Market read

Traders may monitor for follow-through in sentiment/positioning, but the 10b5-1 framing reduces the bearish interpretability.

03

What to watch

The filing does not disclose why the shares were sold or whether other insiders/large holders acted similarly around the same window.

Relevance 6/10Novelty 6/10Timing: filed 2026-06-30 after-hours; reflects sales executed 2026-06-26 to 2026-06-29

Background

SEC Form 4 reports an insider transaction by Guardant Health co-CEO Talasaz AmirAli, including that it was executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health co-CEO Talasaz AmirAli sold ~$39.3M of GH via a 10b5-1 plan across 6 trades at ~$150.49–$153.00.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small versus broader tape/earnings catalysts.

Evidence & confidence

Form 4 provides primary transaction details and the plan is pre-arranged; without accompanying guidance, litigation, or operating news, the fundamental signal is weak.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical catalyst.

None indicated; US-listed biotech/healthcare sentiment only.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect diversification/liquidity needs rather than bearish expectations.

Key entities

  • Guardant Health, Inc.

    Subject of the Form 4 insider sale; co-CEO sold 260,000 shares worth ~$39.3M.

  • Talasaz AmirAli

    Co-Chief Executive Officer and director; executed open-market sales under a 10b5-1 plan.

Related articles

$GHHighAI 9/10

Guardant Health (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.

$GHMedAI 8/10

Guardant Health, Inc. Q2 2026 Earnings Call Summary

Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.

$GHHighAI 9/10

Why is Guardant Health stock surging today?

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade Investing.com -- Guardant Health stock surged 8.8% in after-hours trading after the Palo Alto-based liquid biopsy pioneer reported second-quarter 2026 results that significantly exceeded revenue expectations, with sales reaching $335 million — a 44% year-over-year increase that beat the Wall Street consensus of roughly $314 million by approximately 6.4%.